Novo Nordisk seeks EU nod for higher dose of its weight-loss drug Wegovy
HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 8, 2025: Novo Nordisk A/S has sought approval from the European Medicines Agency for a higher dose of its weight-loss.
HQ Team July 8, 2025: Novartis AG’s treatment for malaria in infants and newborns weighing between two and five kilograms has been approved.
HQ Team July 8, 2025: Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to.
HQ Team July 7, 2025: KalVista Pharmaceuticals Inc.’s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks.
HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.
HQ Team July 3, 2025: The World Health Organization has unveiled a ‘3 by 35 initiative,’ urging governments to impose a health tax.
HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.
HQ Team July 2, 2025: Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after.
HQ Team July 3, 2025: Â The European Commission has approved Vertex Pharmaceuticals‘ drug to treat cystic fibrosis in adults and children above six.
HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.